Sort   by:  
 Page size 
UnknownAdditive impact of HER2-/PTK6-RNAi on interactions with HER3 or IGF-1R leads to reduced breast cancer progression in vivo.
Not available
S-EPMC5528674 | biostudies-literature
UnknownA randomized, phase III trial of capecitabine plus bevacizumab (Cape-Bev) versus capecitabine plus irinotecan plus bevacizumab (CAPIRI-Bev) in first-line treatment of metastatic colorectal cancer: the AIO KRK 0110 trial/ML22011 trial.
Not available
S-EPMC3173448 | biostudies-literature
UnknownDialogue with a conversational agent promotes children's story comprehension via enhancing engagement.
Not available
S-EPMC9299009 | biostudies-literature
UnknownSecreted uPAR isoform 2 (uPAR7b) is a novel direct target of miR-221.
Not available
S-EPMC4480738 | biostudies-literature
UnknownCyr61 and YB-1 are novel interacting partners of uPAR and elevate the malignancy of triple-negative breast cancer.
Not available
S-EPMC5190079 | biostudies-literature
UnknownThree-dimensional microtissues essentially contribute to preclinical validations of therapeutic targets in breast cancer.
Not available
S-EPMC4831289 | biostudies-literature
UnknownPITX2 DNA-methylation predicts response to anthracycline-based adjuvant chemotherapy in triple-negative breast cancer patients.
Not available
S-EPMC5807037 | biostudies-literature
UnknownSymptoms in unilateral vestibular hypofunction are associated with number of catch-up saccades and retinal error: results from the population-based KORA FF4 study.
Not available
S-EPMC10715252 | biostudies-literature
UnknownIdentification of BRCA1-like triple-negative breast cancers by quantitative multiplex-ligation-dependent probe amplification (MLPA) analysis of BRCA1-associated chromosomal regions: a validation study.
Not available
S-EPMC5070367 | biostudies-literature
UnknownSomatic copy number changes in DPYD are associated with lower risk of recurrence in triple-negative breast cancers.
Not available
S-EPMC3817342 | biostudies-literature
Sort   by:  
 Page size